ImmunoPrecise Antibodies Ltd. (IPA.V)
| Previous Close | 8.54 |
| Open | 8.60 |
| Bid | 8.95 x 0 |
| Ask | 8.97 x 0 |
| Day's Range | 8.50 - 9.00 |
| 52 Week Range | 6.39 - 26.25 |
| Volume | 44,525 |
| Avg. Volume | 95,865 |
| Market Cap | 198.294M |
| Beta (5Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 |
| Earnings Date | Mar. 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- Business Wire
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
VICTORIA, British Columbia, August 04, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announces the promotion of Dr. Barry Duplantis, Ph.D., to VP of Client Relations and welcomes Ms. Carla Dahl as VP of Marketing.
- Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
VICTORIA, British Columbia, July 28, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021.
- Business Wire
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
VICTORIA, British Columbia, July 22, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
